Frontlight ResearchEarly access
WithdrawnPhase 2
Exogenous Sodium Lactate Infusion in Traumatic Brain Injury (ELI-TBI)
Key facts
- Who runs it
- University of California, Los Angeles
- Where
- Los Angeles, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Phase
- Phase 2
- Started
- Sept 2020
- Ended
- Jun 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Sodium Lactate
- Placebo
- Record updated
- 15 November 2021
- Why it stopped
- The manufacturer of sodium lactate has stopped making the medication
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Adult patients seen in the Medical Center Emergency Department
- Adult patients transferred to the Neurocritical Intensive Care Unit with a physician's diagnosis of brain injury
- GCS 3-12
Who cannot take part
- Previous severe diminished mental capacity
- History of diabetes mellitus
- History of hemodynamic instability
- Known terminal illness which alters brain functioning
- Diagnosed AIDS progressed to AIDS dementia
- Known history of chronic severe neurological disturbance
- Active neurologic condition such as stroke, recent TBI
- metabolic disorder
- Pregnancy at time of injury
- Severe retardation
- No command of either English or Spanish
- Arrest for a felony
- preexisting hyperlactatemia
- instability precluding experimental intervention
Where in United States
- David Geffen School of Medicine at UCLALos Angeles, United States
About the trial
What the trial wants to find out
Metabolic crisis is a state of energy insufficiency due to impaired mitochondrial function as indicated by cerebral microdialysis lactate/pyruvate ratio (LPR). We have performed preliminary mechanistic analysis of alternative fuels in humans and have demonstrated proof of concept that exogenous fuels alter brain metabolism. We will conduct a multicenter, adaptive design-based, proof of concept phase 2 safety study of candidate supplemental fuels in patients with severe traumatic brain injury to determine safety and efficacy.
The 2 groups in the trial
- ELI ArmTreatment being tested
Infusion of exogenous sodium lactate as supplemental fuel within 48 hours of TBI
Treatment: Sodium Lactate
- PlaceboPlacebo, for comparison
Placebo infusion of normal saline in Part 2 RCT
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- Exogenous lactate infusion (ELI) in traumatic brain injury: higher dose is better?Critical care (London, England), 2025
- Record updated
- 15 November 2021